CliffBio
small molecule

PLENVU

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

Loss of exclusivitySeptember 2033latest FDA-listed patent expiry
CompanySalix Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand namePLENVU
Active ingredientASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Strength7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2018
Marketing statusRX

Listed patents

PatentExpiresType
8999313September 2033product
10918723September 2033use U-2310
12083179September 2033product
10016504September 2033product
9707297September 2033product
9326969September 2033use U-2310
9592252August 2032product
10646512March 2032product
11529368March 2032product
10792306March 2032product
10780112March 2032product

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.